Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 1998 December;10(4) > Minerva Biotecnologica 1998 December;10(4):146-61

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

  MONOCLONAL ANTIBODIES FOR IN VIVO APPLICATIONS - PART II


Minerva Biotecnologica 1998 December;10(4):146-61

language: English

Clinical appli­ca­tions of radio­lab­eled mono­clo­nal anti­bod­ies for can­cer diag­no­sis and ther­a­py

Paganelli G., Chinol M.

Nuclear Medicine Division, European Institute of Oncology, Milan, Italy


FULL TEXT  


In ­recent ­years, con­sid­er­able expe­ri­ence has ­been ­accrued ­through the clin­i­cal appli­ca­tions of radio­lab­eled mono­clo­nal anti­bod­ies in the diag­no­sis and ther­a­py of malig­nant dis­eas­es. While radio­im­mu­nos­cin­ti- gra­phy has estab­lished its ­role in nucle­ar med­i­cine prac­tice, radio­im­mu­no­ther­a­py has ­thus far ­gained lim­it­ed accep­tance main­ly due to the low ­amount of radio­ac­tiv­ity ­that can be tar­get­ed to the ­tumor and to the mye­lo­tox­ic­ity ­which is typ­i­cal­ly the ­dose lim­it­ing fac­tor. Remarkable ­high ther­a­peu­tic ­response ­rates ­have ­been ­obtained for ­tumors ­that are refrac­to­ry to oth­er ther­a­pies ­through the use of loco­re­gion­al admin­is­tra­tion ­that ­allows the deliv­ery of high­er radi­a­tion dos­es to pro­duce cyto­tox­ic ­effects. New strat­e­gies ­based on pre­tar­get­ing tech­niques ­have ­shown ­that, ­unlike direct­ly ­labeled anti­bod­ies, high­er dos­es of radio­ac­tiv­ity can be admin­is­tered system­i­cal­ly with­out asso­ciat­ed ­bone mar­row tox­ic­ity. Pilot stud­ies in ­patients ­with ­high ­grade gli­o­mas, in pro­gres­sion ­after con­ven­tion­al treat­ments, ­have ­shown ­that ­this ­approach inter­feres ­with the pro­gres­sion of ­tumors and pro­duc­es ­tumor regres­sion.

top of page

Publication History

Cite this article as

Corresponding author e-mail